Top news of the week: 03.05.2022.
Startups
Despite biotech slump, veterans of SVB and KKR launch investment firm
Two of the top health care investors at the investment bank SVB Securities and the private equity giant KKR are starting a new biotech investment firm called Enavate Sciences.
A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback.
Battle scars: The journey from lab to patient’s bedside
Whether it’s in the initial R&D, or during the final manufacturing process, taking a drug from a mere concept to a tangible solution is not without
Biotech Venture Capital Investment in China Climbs
Venture-capital investment in Chinese biotechnology startups is rising as the nation’s drug industry turns toward more innovative medications.
Five RNA Therapeutics Startups to Watch in 2022
Five RNA therapeutics startups to watch that have opened their doors since 2020 and are developing the next generation of RNA medicines.
Patient Square Kickstarts Biotech Investment Firm Enavate Sciences
Enavate Sciences launched with an initial capital investment of $300 million from health care investment firm Patient Square Capital. Enavate is a new biotech investment firm.
MISPRO OPENS NEW CONTRACT VIVARIUM FACILITY IN LONG ISLAND CITY, NEW YORK’S NEWEST BIOTECH DESTINATION Learn More
Foresight Diagnostics: Expands Scientific Advisory Board With Appointment of Christopher R. Flowers, M.D., M.S. More MAIA Biotechnology: FDA Orphan Drug Designation for THIO for …
Gene Delivery Start-Up Kelonia Therapeutics Launches with $50 Million
Kelonia has launched with $50 million to create an “off-the-shelf” chimeric antigen receptor to treat hematologic cancer.